Methods of entrapping, inactivating, and removing viral infections by the administration of respiratory tract compositions

• US 20050232868A1
• Filed: 11/02/2004
• Published: 10/20/2005
• Est. Priority Date: 10/19/1999
• Status: Abandoned Application

• Current Assignee: The Procter & Gamble Company
• Original Assignee: The Procter & Gamble Company
• Inventors: Rennie, Paul John, Khanolkar, Jayant Ekanth, Jessen, George William
• Application Number:
  US10/979,498
• Publication Number:
  US 20050232868A1
• Time in Patent Office: Days
• US Class Current: 424/45
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/19 Carboxylic acids, e.g. valproic acid salicylic acid A61K31/60
• CPC Class Codes: A61K 31/28 Compounds containing heavy metals
• CPC Class Codes: A61K 31/315 Zinc compounds
• CPC Class Codes: A61K 31/765 Polymers containing oxygen
• CPC Class Codes: A61K 33/24 Heavy metals; Compounds thereof
• CPC Class Codes: A61K 33/30 Zinc; Compounds thereof
• CPC Class Codes: A61K 45/06 Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• CPC Class Codes: A61P 31/12 Antivirals
• CPC Class Codes: D21H 21/36 Biocidal agents, e.g. fungicidal, bactericidal, insecticidal agents
• CPC Class Codes: D21H 27/32 with materials applied between the sheets attaching together paper or cardboard sheets B31F5/00; adhesives C09J

Abstract

The present invention is directed to methods of preventing and treating respiratory tract viral infections by administering compositions to areas of the respiratory tract such as the nasal cavity, wherein the compositions provide for the encapsulation, inactivation, and/or removal of viruses and/or viral strains associated with the common cold and influenza. The methods of encapsulation, inactivation, and removal of cold and influenza viruses have been shown to create and maintain environments that are hostile to the viruses to result in effective prevention and treatment of cold and influenza-like symptoms.

Claims

19. A method of preventing and treating upper respiratory tract viral infections to result in encapsulation, inactivation, and removal of the viral infections, the method comprises administering a composition to the nasal cavity wherein the composition comprises:

(a) a rheological agent; and

(b) a buffer solution having a pH of from about 3.0 to about 5.5;

wherein the composition has a viscosity of from about 1 cps to about 2000 cps.

20. The method of claim 19 wherein the rheological agent is selected from the group consisting of carboxypolymethylenes, carboxyvinyl polymers, homopolymers of acrylic acid crosslinked with an allyl ether of pentaerythritol, homopolymers of acrylic acid crosslinked with an allyl ether of sucrose, homopolymers of acrylic acid crosslinked with divinyl glycol, natural polymers, polymeric cellulose derivatives, polyvinyl pyrrolidones (PVPs), dextran polymers, polyethylene oxide polymers, thermoreversible polymers, ionic responsive polymers, copolymers of polymethyl vinyl ether and maleic anhydride, and mixtures thereof.

21. The method of claim 20 wherein the rheological agent is a cellulose derivative selected from the group consisting of hydroxypropylmethyl celluloses, hydroxypropyl celluloses, methyl cellulose polymers, carboxymethyl cellulose polymers, salts of carboxymethyl cellulose, and mixtures thereof.

22. The method of claim 20 wherein the rheological agent is a thermoreversible polymer selected from the group consisting of poloxamers, ethylhydroxy ethylcelluloses, and mixtures thereof.

23. The method of claim 19 wherein the buffer solution comprises a buffering agent selected from the group consisting of fumarates, benzoates, lactates, citrates, succinates, tartrates, chlorides, sulphates, phosphates, and mixtures thereof.

24. A method of preventing and treating upper respiratory tract viral infections comprising the steps of:

(a) encapsulating one or more respiratory viruses; and

(b) inactivating the respiratory viruses.

25. The method of claim 24 wherein the encapsulating step comprises the administration of a composition comprising a rheological agent selected from the group consisting of carboxypolymethylenes, carboxyvinyl polymers, homopolymers of acrylic acid crosslinked with an allyl ether of pentaerythritol, homopolymers of acrylic acid crosslinked with an allyl ether of sucrose, homopolymers of acrylic acid crosslinked with divinyl glycol, natural polymers, polymeric cellulose derivatives, polyvinyl pyrrolidones (PVPs), dextran polymers, polyethylene oxide polymers, thermoreversible polymers, ionic responsive polymers, copolymers of polymethyl vinyl ether and maleic anhydride, and mixtures thereof.

26. The method of claim 25 wherein the composition has a viscosity of from about 1 cps to about 2000 cps.

27. The method of claim 26 wherein the composition comprises from about 0.01% to about 30% by weight of the rheological agent.

29. The method of claim 24 wherein the method further comprises the step of:

(c) removing the respiratory viruses from the respiratory tract.

30. The method of claim 29 wherein the removing step comprises the administration of a composition comprising a nasal secretion agent selected from the group consisting of an organic acid, an aromatic plant extract, a hypertonic solution, and mixtures thereof.

31. The method of claim 30 wherein the composition comprises from about 0.001% to about 10% by weight of the nasal secretion agent.

32. The method of claim 31 wherein the composition has a pH in the range of from about 3.0 to about 5.5.

33. The method of claim 32 wherein the composition is a nasal spray comprising from about 40% to about 99.98% by weight of a pharmaceutically acceptable vehicle selected from the group consisting of water, ethanol, propylene glycol, polyethylene glycol, transcutol, glycerol, a liquid aerosol propellant, and mixtures thereof.

28-1. The method of claim 28 wherein the composition comprises from about 0.01% to about 20% by weight of the virus inactivation agent.